We claim:

5 1. A peptide selected from the group having the formulae:

 $R_1 - A^0 - A^1 - A^2 - Asp-Ala-A^5 - A^6 - Thr-A^8 - A^9 - A^{10} - A^{11} - A^{12} - Val-Leu-A^{15} - A^{16} - Leu-Ser-A^{19} - A^{20} - A^{21} - A^{22} - Leu-Gln-Asp-IIe-A^{27} - A^{28} - A^{29} - A^{30} - R_2$

wherein R_1 is a member of the group consisting of a) PhAc, Hca, Dat, IndAc, Ipa, 1-Nac, 2-Nac, 1-Npr, 2-Npr, Ibu; $CH_3(CH_2)_nCO$, or $HOOC(CH_2)_nCO$, where n is an integer from 2 to 20,

10 and b) any other straight chain, branch chain, saturated, unsaturated or poly unsaturated aliphatic carboxyl group of 2-30 carbon atoms and any carbocyclic or heterocyclic aromatic carboxyl group of 3-8 carbon atoms containing at least one atom of the group S, N, and O in the heterocyclic ring, A^o is Phe, D-Phe, Arg, D-Arg, or a carbon-nitrogen single bond,

A1 is Tyr or His,

15 A² is D-Arg or D-Cit,

A5 is lle or Val,

A⁶ is Phe, Tyr, Nal, or Phe(Y), in which Y=F, Cl, Br, or l,

A⁸ is Asn, D-Asn, Cit, D-Cit, Gln, D-Gln, Ser, D-Ser, Thr, D-Thr, Ala, D-Ala, Abu, D-Abu, or Aib, A⁹ is His, D-His, Amp, D-Amp, Gup, or D-Gup,

20 A¹⁰ is Tyr, Tyr(Et), Tyr(Me); Phe(Y), in which Y=H, F, Cl, Br, or I; Amp, His, Cha, Chg, Bpa, Dip, Trp, Trp(For), Tpi, 1-Nal, 2-Nal, 3-Pal, 4-Pal, Phe(NH₂), or Phe(NO₂).

A11 is His, D-His, Arg, D-Arg, Cit, Har, D-Har, Amp, D-Amp, Gup, or D-Gup,

A¹² is Lys, D-Lys, Orn, D-Orn, Har, D-Har, Cit, D-Cit, Nie, or Ala,

A¹⁵ is Gly, Ala, Abu, Aib, Nle, Gln, Cit, or His.

25 A¹⁶ is Gln or Arg,

A¹⁹ is Ala or Abu,

A²⁰ is His, D-His, Arg, D-Arg, or Cit,

A²¹ is Lys, D-Lys, Om, D-Orn, Cit, or D-Cit.

A²² is Leu, Ala or Aib,

30 A²⁷ is Met, Leu, NIe, Abu, or D-Arg.

A²⁸ is Arg, D-Arg, Har, D-Har, Ser, Asn, Asp, Ala, Abu, or Cit,

A²⁹ is Arg, D-Arg, Har, D-Har, Cit, D-Cit, or Agm,

 A^{30} is Arg, D-Arg, Har, D-Har, Cit, D-Cit, Agm, or is a carbon-nitrogen or carbon-oxygen single bond,

35 R_2 is $-NH_2$, $-NH-NH_2$, -NH-OH, $-NHR_3$, $-NR_3R_4$, -OH, or $-OR_3$, in which R_3 and R_4 are any of C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkinyl, C_{7-16} phenylalkyl, $-C_6H_5$, or $-CH(C_6H_5)_2$; provided that if A^{29} is Agm then A^{30} and R_2 are absent, and if A^{30} is Agm then R_2 is absent, and pharmaceutically acceptable salts thereof.

2. The compound of claim 1 wherein one or both of A¹¹ and A²⁰ are other than Arg, D-Arg, 40 or Cit.

- 3. A compound of claim 1 selected from the group consisting of:
- 5 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 67
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 68

- [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, His⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 69
- [CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-15 29)NH₂ Peptide 70
 - [HOOC(CH₂)₈CO-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁸, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 71
- 20 [HOOC(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 72
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 73

- [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Amp⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 74
- [1-Nac-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Amp⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-30 RH(1-29)NH₂ Peptide 75
 - $[CH_3(CH_2)_6CO Tyr^1, D-Arg^2, Phe(pCl)^6, Cit^8, Amp^9, Tyr(Me)^{10}, His^{11}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2$ Peptide 76
- 35 [HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Amp⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 77
 - $[CH_3(CH_2)_6CO Tyr^1, D-Arg^2, Phe(pCI)^6, Cit^8, Amp^9, Tyr(Et)^{10}, His^{11}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2$ Peptide 78

 $[CH_3(CH_2)_6CO - Tyr^1, D-Arg^2, Phe(pCl)^6, Cit^8, His^9, Tyr(Et)^{10}, His^{11}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2$ Peptide 79

 $[CH_3(CH_2)_6CO - Tyr^1, D-Arg^2, Phe(pCl)^6, Ala^8, His^9, Tyr(Et)^{10}, His^{11}, Abu^{15}, Nle^{27}, D-Arg^{28}, 5 Har^{29}lhGH-RH(1-29)NH₂ Peptide 80$

[HOOC(CH₂)₈CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 81

10 [HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 82

[CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, His²⁰, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 86

15

30

[CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, His²⁰, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 87

[HOOC(CH₂)₁2CO-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, His²⁰, Nle²⁷, D-Arg²⁸, 20 Har²⁹]hGH-RH(1-29)NH₂ Peptide 88

[HOOC(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, His²⁰, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 89

25 [1-Nac-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 91

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 92

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Cit¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 93

[CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, His¹⁵, His²⁰, Nle²⁷, D-Arg²⁸, 35 Har²⁹]hGH-RH(1-29)NH₂ Peptide 94

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Orn¹², Abu¹⁵, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 95

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 96

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, 5 Har²⁹]hGH-RH(1-29)NHEt Peptide 97

[CH₃(CH₂)₈CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 98

10 [CH₃(CH₂)₁₀CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 99

[Hca -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 100

15

 $[CH_3(CH_2)_6CO -Tyr^1, D-Arg^2, Phe(pCl)^6, Ala^8, His^9, Tyr(Et)^{10}, His^{11}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NHMe$ Peptide 101

[HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Om¹², Abu¹⁵, His²⁰, Om²¹, 20 Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 102

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Tyr(Et)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 103

25 [CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Dip¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 104

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Phe(pNO₂)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 105

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 106

[HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Tyr(Et)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, 35 Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 107

[HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Dip¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 108

[HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Phe(pNO₂)¹⁰, His¹¹, Om¹², Abu¹⁵, His²⁰, Om²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 109

[HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Om¹², Abu¹⁵, His²⁰, Om²¹, 5 Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 110

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Dip¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 111

10 [CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁸, Phe(pNO₂)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 112

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Tyr(Et)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nie²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 113

15

[CH₃(CH₂)₅CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Dip¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 114

[CH₃(CH₂)₈CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Phe(pNO₂)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, 20 Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 115

[HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁶, Amp⁹, Dip¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 116

25 [HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Phe(pNO₂)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 117

 $[CH_3(CH_2)_6CO - Tyr^1, D-Arg^2, Phe(pCl)^6, Ala^8, Amp^9, Dip^{10}, His^{11}, Orn^{12}, Abu^{15}, His^{20}, Orn^{21}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NHEt$ Peptide 118

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Phe(pNO₂)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 119

[HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Dip¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, 35 Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 120

[HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Phe(pNO₂)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 121

4. A compound of claim 3 selected from the group consisting of :

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 67

5

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁸, His⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 69

[CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁵, Amp⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-10 29)NH₂ Peptide 70

[HOOC(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 72

15

 $[CH_3(CH_2)_6CO -Tyr^1, D-Arg^2, Phe(pCl)^6, Cit^8, Amp^9, Tyr(Me)^{10}, His^{11}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2$ Peptide 76

[HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Amp⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, 20 Har²⁹]hGH-RH(1-29)NH₂ Peptide 77

 $[CH_3(CH_2)_6CO -Tyr^1, D-Arg^2, Phe(pCl)^6, Cit^8, His^9, Tyr(Et)^{10}, His^{11}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2$ Peptide 79

25 [CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu.¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 80

 $[CH_3(CH_2)_6CO-Tyr^1, D-Arg^2, Phe(pCl)^6, Ala^8, His^9, Tyr(Et)^{10}, His^{11}, Abu^{15}, His^{20}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2$ Peptide 86

30

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Om¹², Abu¹⁵, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 95

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Om¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, 35 D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 96

 $[CH_3(CH_2)_6CO -Tyr^1, D-Arg^2, Phe(pCl)^6, Ala^8, His^9, Tyr(Et)^{10}, His^{11}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NHEt Peptide 97$

40 5. A compound selected from the group consisting of:

- [CH₃(CH₂)₄CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 2
- 5 [HOOC(CH₂)₄CO-Tyr¹, D-Arg², Phe(pCl)⁸, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 3
 - [CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 4
- 10 [HOOC(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 5
- [CH₃(CH₂)₈CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
 15 Peptide 6
 - [HOOC(CH₂)₈CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nie²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 7
- 20 [CH₃(CH₂)₁₀CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 8
 - [HOOC(CH₂)₁₀CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 9
 - [CH₃(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 10
- [HOOC(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nie²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ 30 Peptide 11
 - [CH₃(CH₂)₁₄CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 12
- 35 [HOOC(CH₂)₁₄CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 13
 - [CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, Har²⁸, D-Arg²⁹]hGH-RH(1-29)NH₂ Peptide 14

- . [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, Har²⁸, D-Arg²⁹]hGH-RH(1-29)NH₂ Peptide 15
- [CH₃(CH₂)₁₄CO-Phe⁰, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ 5 Peptide 16
- ' [CH₃(CH₂)₁₄CO-D-Phe⁰, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 17
- 10 [PhAc-Arg⁰, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 18
 - [PhAc-D-Arg⁰, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 19
- 15 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 21
- [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Cit⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ 20 Peptide 22
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Arg⁹, Abu¹⁵, Nle²⁷, Har²⁸, D-Arg²⁹]hGH-RH(1-29)NH₂
 Peptide 23
- 25 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Cit⁹, Abu¹⁵, Nle²⁷, Har²⁸, D-Arg²⁹]hGH-RH(1-29)NH₂ Peptide 24
 - [HOOC(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Cit⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 25
- 30 [PhAc-Tyr¹, D-Arg², Phe(pCi)⁶, D-Ala⁸, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 26
- [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Abu⁸, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ 35 Peptide 27
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁹, Abu¹⁵, Nle²⁷, Har²⁸, D-Arg²⁹]hGH-RH(1-29)NH₂ Peptide 28

- [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Amp¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 30
- [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Amp¹o, Abu¹⁵, Nle²¹, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ 5 Peptide 31
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, His¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 32
- 10 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Cha¹⁰, Abu¹⁵, Nle²², D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 33
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tpi¹⁰, Abu¹⁵, Nie²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 34

- [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, 2-Nal¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 35
- [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Dip¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ 20 Peptide 36
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Phe(pNH₂)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
 Peptide 37
- 25 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Trp¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
 Peptide 38
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Phe(pNO₂)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 39

- [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, 3-Pal¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 40
- [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Et)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ 35 Peptide 41
 - [PhAc-His¹, D-Arg², Tyr⁶, Har⁶, Bpa¹⁰, Abu¹⁵, Nle²⊓, D-Arg²⁶, Har²⁶]hGH-RH(1-29)NH₂ Peptide 42

- . [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Har¹², Abu¹⁵, Nle²², D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 43
- [Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt 5 Peptide 45
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 46
- 10 [Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁸]hGH-RH(1-29)NHEt Peptide 47
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 48

- [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Aib¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 49
- [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Orn¹², Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-20 29)NHEt Peptide 50
 - [Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Agm²⁹]hGH-RH(1-29) Peptide 51
- 25 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Agm²⁹]hGH-RH(1-29) Peptide 52
 - [Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁶, Tyr(Me)¹⁰, Abu¹⁵, Nle²², D-Arg²³, Har²⁰]hGH-RH(1-30)NH₂ Peptide 53
- 30 [Dat-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹, Har³⁰]hGH-RH(1-30)NH₂ Peptide 54
- [lpa-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹, Har³⁰]hGH-RH(1-30)NH₂ 35 Peptide 55
 - [Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹, Har³⁰]hGH-RH(1-30)NHEt Peptide 56

[Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, D-Arg²⁹, Har³⁰]hGH-RH(1-30)NH₂ Peptide 57

[Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nie²⁷, D-Arg²⁸, Har²⁹, D-Arg³⁰]hGH-RH(1-5 30)NH₂ Peptide 58

[Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹, Agm³⁰]hGH-RH(1-30) Peptide 59

10 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹, Agm³⁰]hGH-RH(1-30) Peptide 60

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nie²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 62

15

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁸, Tyr(Me)¹⁰, Har¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 63

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Amp¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-20 29)NH₂ Peptide 64

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Cit¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸; Har²⁹]hGH-RH(1-29)NH₂ Peptide 65

25 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, His²⁰, Nie²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 84

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, His²⁰, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 85

30

 $[PhAc-Tyr^1, D-Arg^2, Phe(pCl)^6, Arg^9, Cit^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2$ Peptide 90

6. A peptide of claim 5 selected from the group consisting of:
35 [CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 4

[HOOC(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 5

- [HOOC(CH₂)₈CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 7
- [HOOC(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ 5 Peptide 11
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Cit⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 22
- 10 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁸, 2-Nal¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
 Peptide 35
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Dip¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 36

15 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Phe(pNO₂)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 39

- [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Et)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ 20 Peptide 41
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 62
- A peptide of claim 5 selected from the group consisting of:
 - [CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 4
- 30 [HOOC(CH₂₎₈CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 7
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 21
- 35 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Amp¹⁰, Abu¹⁵, Nie²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 30
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Amp¹o, Abu¹⁵, Nle²⁻, D-Arg²³, Har²³]hGH-RH(1-29)NH₂ Peptide 31

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Phe(pNH₂)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
Peptide 37

- [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Et)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
 5 Peptide 41
 - [PhAc-His¹, D-Arg², Tyr⁵, Har⁵, Bpa¹o, Abu¹⁵, Nle²², D-Arg²⁵, Har²⁵]hGH-RH(1-29)NH₂ Peptide 42
- 10 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nle²², D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 62
 - 8. The use of a compound of any of claims 1, , or 5 for the production of a pharmaceutical composition for suppressing levels of GH in a patient in need of same.
 - 9. The use of a compound of any of claims 1, , or 5 for the production of a pharmaceutical composition for suppressing IGF-I or IGF-II levels in the tumor tissue of a patient having a cancer carrying receptors for IGF-I.
- 20 10. The use of a compound of any of claims 1, or 5 for the production of a pharmaceutical composition for suppressing VEGF levels in the tumor tissue of a patient having a cancer.
- 11. The use of a compound of any of claims 1, or 5 for the production of a pharmaceutical composition for suppressing levels of IGF-I in a patient in need of same.
 25
 - 12. The use of a compound of any of claims 1, or 5 for the production of a pharmaceutical composition for suppressing serum IGF-I levels in a patient having a cancer carrying receptors for IGF-I.
- 30 13. The use of a compound of any of claims 1, or 5 for the production of a pharmaceutical composition for suppressing GH levels in a patient having a cancer carrying receptors for IGF-I or GH.
- 14. The use of a compound of any of claims 1, or 5 for the production of a pharmaceutical 35 composition for blocking GH-RH receptors in a patient having a cancer carrying receptors for GH-RH.
 - 15. The method of suppressing levels of GH in a patient in need of same by administering to said patient a suppressively effective amount of a compound of any of claims 1, or 5.

16. The method of suppressing IGF-I or IGF-II levels in the tumor tissue of a patient having a cancer carrying receptors for IGF-I by administering to said patient a suppressively effective amount of a compound of any of claims 1, or 5.

- 5 17. The method of suppressing VEGF levels in the tumor tissue of a patient having a cancer by administering to said patient a suppressively effective amount of a compound of any of claims 1, or 5.
- 18. The method of suppressing levels of IGF-I in a patient in need of same by 10 administering to said patient a suppressively effective amount of a compound of any of claims 1, or 5.
- 19. The method of suppressing serum IGF-I levels in a patient having a cancer carrying receptors for IGF-I by administering to said patient a suppressively effective amount of a 15 compound of any of claims 1, or 5.
 - 20. The method of suppressing GH levels in a patient having a cancer carrying receptors for IGF-I or GH by administering to said patient a suppressively effective amount of a compound of any of claims 1, or 5.

- 21. The method of the treatment of a patient having a cancer carrying receptors for GH-RH by administering to said patient an amount of a compound of any of claims 1, or 5 effective to block said GH-RH receptors
- 25 22. A pharmacologically administrable composition for the suppression of levels of GH in a patient consisting essentially of a compound of claim 1, or 5 and a pharmacologically acceptable carrier.
- 23. A pharmacologically administrable composition for the suppression of —IGF-I or IGF-II 30 levels in the tumor tissue of a patient having a cancer carrying receptors for IGF-I consisting essentially of a compound of claim 1, or 5 and a pharmacologically acceptable carrier.
- 24. A pharmacologically administrable composition for the suppression of VEGF levels in the tumor tissue of a patient having a cancer consisting essentially of a compound of claim 1, or 5 35 and a pharmacologically acceptable carrier.
 - 25. A pharmacologically administrable composition for the suppression of levels of IGF-I in a patient consisting essentially of a compound of claim 1, or 5 and a pharmacologically acceptable carrier.

- 26. A pharmacologically administrable composition for the suppression of GH levels in a patient having a cancer carrying receptors for IGF-I or GH consisting essentially of a compound of claim 1, or 5 and a pharmacologically acceptable carrier.
- 5 27. A pharmacologically administrable composition for the suppression of IGF-I levels in a patient having a cancer carrying receptors for IGF-I consisting essentially of a compound of claim 1, or 5 and a pharmacologically acceptable carrier.
- 28. A pharmacologically administrable composition for blocking receptors for GH-RH in a 10 patient having a cancer carrying receptors for GH-RH consisting essentially of a compound of claim 1, or 5 and a pharmacologically acceptable carrier.